Comparative Pharmacology
Head-to-head clinical analysis: ETHMOZINE versus PRONESTYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHMOZINE versus PRONESTYL.
ETHMOZINE vs PRONESTYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ic antiarrhythmic; blocks cardiac sodium channels, slowing phase 0 depolarization and reducing conduction velocity in atrial and ventricular myocardium.
Class IA antiarrhythmic; blocks sodium channels, decreases phase 0 upstroke velocity, prolongs action potential duration, and increases effective refractory period.
200-300 mg orally every 8 hours; maximum 900 mg/day.
For life-threatening ventricular arrhythmias: loading dose of 100 mg IV over 5 minutes, repeated every 5 minutes as needed up to a total of 1 g. Maintenance: continuous IV infusion of 1-4 mg/min. Oral: 50 mg/kg/day in divided doses every 3-6 hours.
None Documented
None Documented
3-12 hours (mean ~6 hours); prolonged in hepatic or renal impairment.
3-5 hours in patients with normal renal function; prolonged to 10-20 hours in renal impairment. Clinical context: Requires dosing every 3-4 hours to maintain therapeutic levels; sustained-release formulations allow Q6-8h dosing.
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for <1% of a dose; approximately 10-20% excreted in feces via bile.
Renal excretion accounts for approximately 50-60% of procainamide elimination as unchanged drug, with an additional 10-30% as the active metabolite N-acetylprocainamide (NAPA). Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Antiarrhythmic
Antiarrhythmic